FindTrial
Sign In

Cirtuvivint

DRUG5 trials

Sponsors

Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas, National Cancer Institute (NCI), University of Colorado, Denver, Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas, Washington University School of Medicine

Conditions

Acute Myeloid LeukemiaEndometrioid Ovarian CancerFallopian Tube CancerMyelodysplastic SyndromeMyelodysplastic Syndrome/Acute Myeloid LeukemiaPrimary Peritoneal CancerRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic Syndrome

Phase 1

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
RecruitingNCT06484062
National Cancer Institute (NCI)Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia +6
Start: 2025-08-15End: 2028-06-01Target: 54Updated: 2026-06-11
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
RecruitingNCT06856499
University of Colorado, DenverEndometrioid Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Start: 2025-12-08End: 2030-09-01Target: 50Updated: 2026-07-24
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RecruitingNCT07155200
Washington University School of MedicineSmall-cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung Carcinoma
Start: 2025-12-18End: 2029-01-31Target: 42Updated: 2026-08-12

Phase 2

Multicenter, Open-Label Phase II Trial of Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
RecruitingCTIS2024-511987-10-00
Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En SarcomasSelected Advanced Soft-Tissue Sarcomas
Start: 2025-04-07Target: 28Updated: 2025-10-09
Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
RecruitingNCT07032285
Asociación Europea y Latinoamericana SELNET para la Investigación en SarcomasSoft Tissue Sarcoma (STS)
Start: 2025-01-15End: 2027-07-30Target: 25Updated: 2026-04-06

Related Papers

Abstract 1167: The pan-CLK DYRK inhibitor SM09419 prolongs animal survival times in a subset of pediatric medulloblastoma patient-derived orthotopic xenograft mouse models.
Cancer Research2026-04-03
Dynamic switching of apoptosis-modulating BIM heterodimers in response to BH3 mimetics in xenograft models of hematologic malignancies.
2026-03-17
Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML)
Blood2025-11-03
Abstract 7041: The CLK/DYRK inhibitor SM09419 shows potent efficacy across a broad panel of pediatric preclinical xenograft models - A report from the Pediatric Preclinical In Vivo Testing Consortium (PIVOT)
Cancer Research2025-04-21